Kiniksa Pharmaceuticals International PLC (KNSA)
21.11
-0.06
(-0.30%)
USD |
NASDAQ |
Dec 04, 16:00
21.11
0.00 (0.00%)
After-Hours: 20:00
Kiniksa Pharmaceuticals International Enterprise Value: 1.305B for Dec. 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| December 03, 2024 | 1.305B |
| December 02, 2024 | 1.354B |
| November 29, 2024 | 1.370B |
| November 27, 2024 | 1.388B |
| November 26, 2024 | 1.368B |
| November 25, 2024 | 1.350B |
| November 22, 2024 | 1.313B |
| November 21, 2024 | 1.299B |
| November 20, 2024 | 1.308B |
| November 19, 2024 | 1.279B |
| November 18, 2024 | 1.329B |
| November 15, 2024 | 1.313B |
| November 14, 2024 | 1.351B |
| November 13, 2024 | 1.409B |
| November 12, 2024 | 1.436B |
| November 11, 2024 | 1.440B |
| November 08, 2024 | 1.427B |
| November 07, 2024 | 1.438B |
| November 06, 2024 | 1.439B |
| November 05, 2024 | 1.367B |
| November 04, 2024 | 1.327B |
| November 01, 2024 | 1.399B |
| October 31, 2024 | 1.407B |
| October 30, 2024 | 1.438B |
| October 29, 2024 | 1.456B |
| Date | Value |
|---|---|
| October 28, 2024 | 1.768B |
| October 25, 2024 | 1.757B |
| October 24, 2024 | 1.719B |
| October 23, 2024 | 1.713B |
| October 22, 2024 | 1.709B |
| October 21, 2024 | 1.644B |
| October 18, 2024 | 1.671B |
| October 17, 2024 | 1.706B |
| October 16, 2024 | 1.675B |
| October 15, 2024 | 1.729B |
| October 14, 2024 | 1.698B |
| October 11, 2024 | 1.693B |
| October 10, 2024 | 1.616B |
| October 09, 2024 | 1.575B |
| October 08, 2024 | 1.542B |
| October 07, 2024 | 1.489B |
| October 04, 2024 | 1.543B |
| October 03, 2024 | 1.529B |
| October 02, 2024 | 1.546B |
| October 01, 2024 | 1.614B |
| September 30, 2024 | 1.579B |
| September 27, 2024 | 1.562B |
| September 26, 2024 | 1.488B |
| September 25, 2024 | 1.498B |
| September 24, 2024 | 1.523B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
288.42M
Minimum
Dec 05 2019
1.768B
Maximum
Oct 28 2024
876.82M
Average
831.44M
Median
Enterprise Value Benchmarks
| Pfizer Inc | 201.79B |
| NovaBay Pharmaceuticals Inc | 2.076M |
| Palatin Technologies Inc | 18.73M |
| iBio Inc | 13.68M |
| Theriva Biologics Inc | -12.63M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -12.69M |
| Revenue (Quarterly) | 112.21M |
| Total Expenses (Quarterly) | 121.87M |
| EPS Diluted (Quarterly) | -0.18 |
| Gross Profit Margin (Quarterly) | 55.96% |
| Profit Margin (Quarterly) | -11.31% |
| Earnings Yield | -0.66% |
| Normalized Earnings Yield | -0.6633 |